MedTrace Logo

De Novo Lipogenesis in Severity of NAFLD

NCT03683589 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 49

Last updated 2024-12-19

No results posted yet for this study

Summary

NAFLD is the most prevalent liver disease in the U.S., and there is a serious need to understand its progression to the advanced state, nonalcoholic steatohepatitis (NASH). Previous studies has shown that elevated de novo lipogenesis (DNL) is the unique, early event distinguishing patients with NAFLD from equally-obese subjects with low IHTG. The purpose of this study is to directly by measure DNL in human liver tissue and comparing it to liver histological scores from patient biopsies.

Conditions

Sponsors & Collaborators

  • American Society for Nutrition

    collaborator OTHER

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    collaborator NIH

  • University of Missouri-Columbia

    lead OTHER

Principal Investigators

  • Elizabeth J Parks, PhD · University of Missouri-Columbia

Eligibility

Min Age
22 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-01
Primary Completion
2019-08-21
Completion
2020-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03683589 on ClinicalTrials.gov